About Primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement
Primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement is a rare disease catalogued by Orphanet (ORPHA:2196). It is associated with the CLDN19 gene. Search below for active recruiting clinical trials from ClinicalTrials.gov, or visit the Orphanet expert page for specialist centres, natural history studies, and patient registries.
Clinical Trial Eligibility Tips
What to know before applying to Primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement trials.
Search ClinicalTrials.gov for "Primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement" or filter by Orphanet code ORPHA:2196 to find disease-specific studies.
Ask your specialist to refer you to a Centre of Expertise — Orphanet lists all accredited centres for this condition worldwide.
Natural history studies and patient registries often enrol before drug trials open — contact the Orphanet patient community first.
Patient Resources
Find recruiting Primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement. Updated daily.